You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria

Article Text

Article menu

Download PDFPDF

Abstracts Accepted for Publication
Diagnostics and imaging procedures
AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria
Free
  1. MB Axelsen1,
  2. H Bliddal2,
  3. LTH Jacobssen3,
  4. MS Hansen4,
  5. A Dudek5,
  6. M Rell-Bakalarska6,
  7. M Boesen7,
  8. J Stefanek8,
  9. B Sundman-Engberg9,
  10. M Østergaard1
  1. 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet
  2. 2The Parker Institute, Hospital Frederiksberg-Bispebjerg, Copenhagen, Denmark
  3. 3Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
  4. 4Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Denmark
  5. 5Centrum Medyczne MEDENS S.C., Wojewodztwo slaskie
  6. 6Rheumatology, Rheumatology, Poland, Poland
  7. 7Department of Radiology, The Parker Institute, Hospital Frederiksberg-Bispebjerg, Copenhagen, Denmark
  8. 8UCB Biosciences GmbH, Monheim, Germany
  9. 9UCB Pharma AB, Stockholm, Sweden

Abstract

Background Dynamic contrast-enhanced MRI (DCE-MRI) has been proposed for evaluating treatment response in RA. In a 16-week anti-TNF trial, DCE-MRI measures of inflammation analyzed for regions of interest (ROIs) covering MCP joints 2–5 and PIP joints 2–5 detected improvements at week 16, but not at earlier time point1.

Objectives To investigate if solely analyzing joints fulfilling predefined MRI quality criteria for joint visualization would increase the responsiveness and discrimination between treatments of DCE-MRI.

Methods Patients with active RA despite stable DMARD therapy for ≥12 weeks were randomized 2:1 to certolizumab pegol (CZP) or 2 weeks of placebo (PBO) followed by CZP (CZP+PBO). MRIs were obtained at weeks 0 (baseline), 1, 2, 4, 8 and 16. Only joints fulfilling MRI joint quality criteria (≥3MCP/≥2PIP joint slices including the distal and/or the proximal bone of the joint and part of the joint cavity) were included in analyses. ROIs covering each joint were analyzed for number of enhancing voxels (Nvoxel), initial rate of enhancement (IRE) and maximum enhancement (ME) using the DYNAMIKA software (Image Analysis, UK).

Results For 38 (CZP: 26; PBO+CZP: 12) of the 40 randomized patients, ≥1 joint fulfilled the quality criteria at baseline. 31 MCP2, 28 MCP3, 23 MCP4, 7 MCP5, 29 PIP2, 29 PIP3, 28 PIP4 and 12 PIP5 joints were included. No individual joints showed significant changes over time or differences between groups. Analyses by joint group (MCP2–4 and PIP2–4) had few data available. Nvoxel and ME decreased numerically, but not significantly, for PIP2–4.

View this table:
Table 1.

Baseline values of and changes in DCE-MRI parameters for MCP2–4 and PIP2–4

Conclusions There were no statistically significant changes in DCE-MRI on joint level or joint group level or between groups. Applying strict joint coverage quality criteria compromises the statistical power of the DCE-MRI analyses underlining the importance of standardization of the method.

References

  1. Østergaard. Arthritis Rheum 2014;66(Suppl. 10):518.

References

Disclosure of Interest M. B. Axelsen Grant/research support from: UCB Nordic funded the study, H. Bliddal Grant/research support from: UCB Nordic, L. T. H. Jacobssen Consultant for: Abbvie, Celegen, MSD, Novartis and UCB, M. Hansen: None declared, A. Dudek: None declared, M. Rell-Bakalarska: None declared, M. Boesen Consultant for: Chairman of the clinical advisory board Image Analysis, LTD London, J. Stefanek: None declared, B. Sundman-Engberg: None declared, M. Østergaard Grant/research support from: and/or speaking/consultant fees: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB, and Wyeth

http://dx.doi.org/10.1136/annrheumdis-2017-eular.1946

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.